• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery.成年低级别胶质瘤患者术后5年随访期内肿瘤进展的预测因素
Front Surg. 2022 Oct 5;9:937556. doi: 10.3389/fsurg.2022.937556. eCollection 2022.
2
Predicting factors of tumor progression in adult patients with low-grade glioma within five years after surgery.成人低级别胶质瘤患者术后五年内肿瘤进展的预测因素
Transl Cancer Res. 2021 Apr;10(4):1907-1915. doi: 10.21037/tcr-21-589.
3
Insular glioma resection: assessment of patient morbidity, survival, and tumor progression.岛叶胶质瘤切除术:患者发病率、生存率和肿瘤进展评估。
J Neurosurg. 2010 Jan;112(1):1-9. doi: 10.3171/2009.6.JNS0952.
4
Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma.放疗(无论是否联合化疗)对神经胶质瘤的长期神经认知及其他副作用
Cochrane Database Syst Rev. 2019 Aug 5;8(8):CD013047. doi: 10.1002/14651858.CD013047.pub2.
5
Surgical management of incidentally discovered diffusely infiltrating low-grade glioma.偶然发现的弥漫浸润性低级别胶质瘤的外科治疗。
J Neurosurg. 2018 Jul;129(1):19-26. doi: 10.3171/2017.3.JNS17159. Epub 2017 Oct 6.
6
Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas.成人半球低级别胶质瘤切除后的复发和恶性转化。
J Neurosurg. 2010 Jan;112(1):10-7. doi: 10.3171/2008.10.JNS08608.
7
Contribution of combined intraoperative electrophysiological investigation with 3-T intraoperative MRI for awake cerebral glioma surgery: comprehensive review of the clinical implications and radiological outcomes.术中联合电生理检查与3-T术中磁共振成像在清醒脑胶质瘤手术中的作用:临床意义及影像学结果的综合综述
Neurosurg Focus. 2016 Mar;40(3):E14. doi: 10.3171/2015.12.FOCUS15572.
8
Risk factors for early progression of diffuse low-grade glioma in adults.成人弥漫性低级别胶质瘤早期进展的危险因素
Chin Neurosurg J. 2022 Oct 1;8(1):25. doi: 10.1186/s41016-022-00295-z.
9
Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article.低级别胶质瘤在功能区的手术:切除范围的体积分析及其对总生存的影响。单机构 190 例经验:临床文章。
J Neurosurg. 2012 Dec;117(6):1039-52. doi: 10.3171/2012.8.JNS12393. Epub 2012 Oct 5.
10
Increased signal intensity in FLAIR sequences in the resection cavity can predict progression and progression-free survival in gliomas.切除腔内液体衰减反转恢复序列(FLAIR)信号强度增加可预测胶质瘤的进展及无进展生存期。
Neurocirugia (Astur). 2016 Nov-Dec;27(6):269-276. doi: 10.1016/j.neucir.2016.04.002. Epub 2016 May 24.

引用本文的文献

1
Dosimetric comparison of advanced radiation techniques for scalp-sparing in low-grade gliomas.低级别胶质瘤保头皮的先进放疗技术的剂量学比较
Strahlenther Onkol. 2024 Sep;200(9):785-796. doi: 10.1007/s00066-024-02229-3. Epub 2024 Apr 22.
2
Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas.转化生长因子β2(TGFB2)信使核糖核酸水平,与干扰素调节因子5(IRF5)的干扰素-γ受体激活及CD276/B7-H3的表达相结合,是低级别胶质瘤中可作为治疗靶点的负性预后标志物。
Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202.
3
Neurophysiologic cut off values for safe resection of patients with supratentorial gliomas.幕上胶质瘤患者安全切除的神经生理学临界值。
Acta Neurochir (Wien). 2023 Dec;165(12):4227-4234. doi: 10.1007/s00701-023-05865-3. Epub 2023 Nov 2.

本文引用的文献

1
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.低级别胶质瘤中与复发和恶性进展相关的生物标志物及其在免疫治疗中的作用。
Front Immunol. 2022 May 23;13:899710. doi: 10.3389/fimmu.2022.899710. eCollection 2022.
2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类:概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
Low-Grade Glioma Case Series: Lessons Learned from an Evolving 10-Year Single-Institution Multidisciplinary Team Practice.低级别胶质瘤病例系列:单机构多学科团队 10 年实践经验教训。
World Neurosurg. 2021 Jul;151:e47-e57. doi: 10.1016/j.wneu.2021.03.101. Epub 2021 Mar 26.
4
Predicting the Extent of Resection in Low-Grade Glioma by Using Intratumoral Tractography to Detect Eloquent Fascicles Within the Tumor.利用肿瘤内纤维束成像检测肿瘤内明确的神经束来预测低级别胶质瘤的切除范围
Neurosurgery. 2021 Jan 13;88(2):E190-E202. doi: 10.1093/neuros/nyaa463.
5
Neutrophil-to-Lymphocyte Ratio and Its Changes are Related to Grade II-IV Glioma Recurrence.中性粒细胞与淋巴细胞比值及其变化与II-IV级胶质瘤复发相关。
Cancer Manag Res. 2020 Sep 30;12:9429-9434. doi: 10.2147/CMAR.S267523. eCollection 2020.
6
Current clinical management of elderly patients with glioma.当前老年胶质细胞瘤患者的临床治疗管理。
Expert Rev Anticancer Ther. 2020 Dec;20(12):1037-1048. doi: 10.1080/14737140.2020.1828867. Epub 2020 Oct 8.
7
Risk Stratification in Low Grade Glioma: A Single Institutional Experience.低级别胶质瘤的风险分层:单机构经验
Neurol India. 2020 Jul-Aug;68(4):803-812. doi: 10.4103/0028-3886.293441.
8
Establishment of age group classification for risk stratification in glioma patients.建立年龄组分类以对胶质瘤患者进行风险分层。
BMC Neurol. 2020 Aug 20;20(1):310. doi: 10.1186/s12883-020-01888-w.
9
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development.进一步了解胶质瘤发病机制:对治疗开发的启示。
Expert Rev Anticancer Ther. 2020 May;20(5):355-363. doi: 10.1080/14737140.2020.1757440. Epub 2020 May 12.
10
Multimodality Imaging Techniques to Assist Surgery in Low-Grade Gliomas.辅助低级别胶质瘤手术的多模态成像技术
World Neurosurg. 2020 Jan;133:423-425. doi: 10.1016/j.wneu.2019.10.120.

成年低级别胶质瘤患者术后5年随访期内肿瘤进展的预测因素

Predictors of tumor progression of low-grade glioma in adult patients within 5 years follow-up after surgery.

作者信息

Yan Zhiqiang, Wang Jiang, Dong Qiufeng, Zhu Lian, Lin Wei, Jiang Xiaofan

机构信息

Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

出版信息

Front Surg. 2022 Oct 5;9:937556. doi: 10.3389/fsurg.2022.937556. eCollection 2022.

DOI:10.3389/fsurg.2022.937556
PMID:36277286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9581165/
Abstract

BACKGROUND

Glioma originates from glial cells in the brain and is the most common primary intracranial tumor. This study intends to use a retrospective analysis to explore the factors that can predict tumor progression in adult low-grade gliomas, namely WHO II grade patients, within 5 years after surgery.

METHODS

Patients with WHO grade II glioma who were surgically treated in our hospital from February 2011 to May 2017 were included. According to the inclusion and exclusion criteria, 252 patients were included in the final analysis. According to the results of the 5-year follow-up (including survival and imaging review results), patients were divided into progression-free group and progression group. Univariate and multivariate analysis were conducted to investigate the related factors of tumor progression during the 5-year follow-up.

RESULTS

The results of the 5-year follow-up showed that 111 (44.0%) cases had no progress (progression free group, PFG), 141 (56.0%) cases had progress (progression group, PG), of which 43 (30.5%) cases were operated again, 37 cases (26.2%) received non-surgical treatments. There were 26 (10.3%) all-cause deaths, and 21 (8.3%) tumor-related deaths. Univariate and multivariate analysis showed that age >45 years old (OR = 1.35, 95% CI, 1.07-3.19,  = 0.027), partial tumor resection (OR = 1.66, 95% CI, 1.15-3.64,  = 0.031), tumor diameter >3 cm (OR = 1.52, 95% CI, 1.14-4.06,  = 0.017) and no radiotherapy (OR = 1.37, 95% CI, 1.12-2.44,  = 0.039) were independent predictors of the progression of tumor during the 5-year follow-up period.

CONCLUSION

Age >45 years old, partial tumor resection, tumor diameter >3 cm, no radiotherapy are predictors for tumor progression for glioma patients after surgery.

摘要

背景

胶质瘤起源于脑内的胶质细胞,是最常见的原发性颅内肿瘤。本研究旨在采用回顾性分析方法,探讨可预测成人低级别胶质瘤(即世界卫生组织II级患者)术后5年内肿瘤进展的因素。

方法

纳入2011年2月至2017年5月在我院接受手术治疗的世界卫生组织II级胶质瘤患者。根据纳入和排除标准,最终纳入252例患者进行分析。根据5年随访结果(包括生存情况和影像学复查结果),将患者分为无进展组和进展组。进行单因素和多因素分析,以研究5年随访期间肿瘤进展的相关因素。

结果

5年随访结果显示,111例(44.0%)无进展(无进展组,PFG),141例(56.0%)有进展(进展组,PG),其中43例(30.5%)再次手术,37例(26.2%)接受非手术治疗。全因死亡26例(10.3%),肿瘤相关死亡21例(8.3%)。单因素和多因素分析显示,年龄>45岁(OR = 1.35,95%CI,1.07 - 3.19,P = 0.027)、肿瘤部分切除(OR = 1.66,95%CI,1.15 - 3.64,P = 0.